ClinicalTrials.gg
CompletedNCT03422328UMBRELLAUpdated Apr 27, 2025

A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

A Phase 3 interventional study of macitentan in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension, sponsored by Actelion. Completed at 34 sites in 7 countries. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing macitentan in Pulmonary Arterial Hypertension — 1 open to participants now, 2 under way, 2 of them phase 3. macitentan · Pulmonary Arterial Hypertension.

Enrollment
10th of 18
151 · median 156
Started
2018
with 1 other
Phase 3
13 of 18
1 open now
Registered
14th of 18
by date
Lead sponsor
15 of 18
Actelion

Among the 18 studies testing macitentan in Pulmonary Arterial Hypertension, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 3, and was the 14th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing macitentan in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About macitentan

macitentan: first FDA approval 2013 (OPSUMIT), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing macitentan in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH) who were previously treated with macitentan in clinical studies.

Read the detailed description

The purpose of this study is to provide continued treatment with macitentan to subjects with PAH or CTEPH who participated in "parent studies" and to continue to accrue long-term safety data. The design of this study is widely used in clinical programs to give participants in a clinical study access to an effective study treatment beyond completion of the parent study. This is considered the best option to collect long-term safety and tolerability information of macitentan 10 mg and survival status of participants with PAH and CTEPH. "Parent study/studies" refer to a number of clinical studies with macitentan that are conducted in different clinical classification of PAH and CTEPH (NCT00667823, NCT02112487, NCT02310672, NCT02968901, NCT02558231, NCT02382016, NCT02060721) and may be completed before the participants have access to commercial macitentan in their country of residence. The "parent studies" are fully or partially running in countries where no access to commercial macitentan is expected in the near future.

03

Conditions studied

  • Pulmonary Arterial Hypertension
  • Chronic Thromboembolic Pulmonary Hypertension

Keywords

  • macitentan
  • long-term safety
  • open-label
  • single-arm
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed to take part in the study before any study mandated procedure.
  2. Participants from one of the parent studies and: a) the sponsor has decided to terminate the parent study in that country and b) the participant has completed the end of treatment (EOT) Visit of the parent study
  3. Women of are able to take part in the study if the following applies: a) Urine pregnancy test is negative at Enrollment; b) Agreement to perform monthly urine or serum pregnancy tests during the study and up to at least 30 days after the study treatment discontinuation; and c) Agreement to adhere to the planned scheme from Enrollment up to at least 30 days after study treatment discontinuation

Exclusion criteria

Exclusion Criteria:

  1. less than 80 gram per liter (g/L)
  2. Serum (AST) and/or alanine aminotransferases (ALT) more than three times the
  3. Known and documented history of severe hepatic impairment that is Class C.
  4. Pregnant, planning to become pregnant, or breastfeeding
  5. Known to macitentan, its , or drugs of the same class
  6. Planned or current treatment with another treatment up to 3 months prior to Enrollment
  7. Any known factor or disease that may interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease
  8. Treatment with a strong inhibitor (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Open-label macitentan 10 mg

    10 mg macitentan film coated tablet, administered orally once daily

    Drug: macitentan

Interventions

  • macitentan 10 mg, film-coated tablet, oral use

    Also known as: ACT-064992, JNJ-67896062

06

What researchers measure

Primary outcomes

  1. Incident Rate of Treatment-emergent Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A treatment-emergent AE is any AE temporally associated with the use of study treatment.

    Time frame: From Day 1 to End of study (EoS) visit (an average of 3 years)

  2. Incident rate of treatment-emergent adverse events (AEs) leading to premature discontinuation of study treatment

    Any AE will be recorded that 1) is (temporally) associated with the use of study treatment whether or not considered by the investigator as related to study treatment and 2) leads to premature discontinuation of study medication.

    Time frame: From Day 1 to EoS visit (an average of 3 years)

  3. Incident rate of treatment-emergent serious adverse events (SAEs)

    Any SAE as defined by the ICH guidelines will be recorded. Any hepatic AE that leads to discontinuation of study treatment will be defined as SAE.

    Time frame: From Day 1 to EoS visit (an average of 3 years)

  4. Number of pregnancies with maternal exposure to macitentan

    Pregnancies with maternal exposure to macitentan will be recorded.

    Time frame: From Day 1 to EoS visit (an average of 3 years)

Other outcomes

  1. Change of WHO functional class to each scheduled time point

    The proportion of patients who worsened, remain unchanged or improved from baseline to each scheduled time-point in WHO function will be calculated, where baseline is the initial baseline from the "parent study" (or the double-blind core study preceding the "parent study").

    Time frame: From Day 1 to EoT visit (an average of 3 years)

  2. Assessment of survival status at End-of-Study (EoS)

    Time to death of all causes up to EoS from the date of randomization or enrollment in the "parent study" (or the double-blind core study preceding the "parent study") will be estimated.

    Time frame: From Day 1 to EoS visit (an average of 3 years)

07

Study locations

34 sites
  • The Republican Scientific-Practical Center ''Cardiology''
    Minsk, 220036, Belarus
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHRU Besancon Hopital Jean Minjoz
    Besancon, 25030, France
  • CHU de Bordeaux - Hospital Haut-Leveque
    Bordeaux (Pessac), 33604, France
  • CHU de la Cavale Blanche
    Brest Cedex 2, 29609, France
  • GH est - Hôpital Cardiovasculaire et Pneumologie Louis Pradel
    Bron Cedex, 69677, France
  • Hôpital Côte de Nacre
    Caen Cedex, France
  • CHU Dijon
    Dijon Cedex, 21079, France
  • CHU Grenoble
    Grenoble, 38700, France
  • Hopital Bicetre Aphp Hopitaux Universitaires Paris Sud
    Le Kremlin Bicetre cedex, 94275, France
  • Hôpital Cardiologique - Chru Lille
    Lille Cedex, 59037, France
  • CHU de Limoges
    Limoges Cedex, 87042, France
  • CHU de la Timone
    Marseille cedex 5, 13005, France
  • CHU de Montpellier - Arnaud de Villeneuve
    Montpellier, 34295, France
  • CHU Nantes - Hopital Nord Laënnec
    Nantes Cedex 1, 44093, France
  • Centre Hospitalier Universitaire - de Nice - Hopital Pasteur
    Nice, 06001, France
  • Hopital Europeen Georges Pompidou
    Paris Cedex 15, 75908, France
  • CHU de Reims
    Reims, 51100, France
  • Chu Rennes Hopital Pontchaillou
    Rennes, 35033, France
  • CHU Rouen Hopital Charles Nicolle
    Rouen, 76031, France
  • CHU Saint Etienne Hopital Nord
    St Priest en Jarez Cedex, 42277, France
  • Nouvel Hopital Civil
    Strasbourg, 67091, France
  • Hopital Larrey CHU de Toulouse
    Toulouse Cedex 9, France
  • CHU de Nancy - Hopital de Brabois
    Vandoeuvre les Nancy Cedex, 54511, France
  • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
    Lublin, 20 718, Poland
  • Wojewodzki Szpital Specjalistyczny Oddzial Kardiologiczny
    Wroclaw, 51 124, Poland
  • Cardiovascular Pathology Research Institute of Siberian Branch of RAMS
    Kemerovo, 650002, Russian Federation
  • National Medical Research Center of Cardiology of MoH of Russian Federation
    Moscow, 121552, Russian Federation
  • Federal State Budgetary Institution Of Ministry Of Health Of Russian Federation
    Novosibirsk, 630055, Russian Federation
  • Federal North-West Medical Research Centre
    Saint-Petersburg, 197341, Russian Federation
  • Federal State Budget Scientific Institution
    Tomsk, 634012, Russian Federation
  • Istanbul University Istanbul Medical Faculty
    Capa_Istanbul, 34093, Turkey
  • CE 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery'
    Dnipro, 49059, Ukraine
  • Lviv Regional Clinical Hospital
    Lviv, 79000, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Dec 2023, 68 months.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 68 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 5, 2018
StartActual
Apr 5, 2018
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 27, 2023
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03422328
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Apr 5, 2018
Primary completion
Dec 27, 2023
Completion
Dec 27, 2023
Last update
Apr 27, 2025

Study contacts

Marek Sochor
study director · Actelion

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Macitentan

Start the discussion